Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Toxicity management in severe and refractory cases—what we have learned

Toxicity management in severe and refractory cases—what we have learned editorial memo (2022) 15:4 https://doi.org/10.1007/s12254-021-00788-0 Toxicity management in severe and refractory cases—what we have learned Matthias Preusser Accepted: 2 December 2021 © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2021 In this issue of the Magazine of European Medical On- Overall, the current collection of articles provides cology (MEMO), we provide a series of articles sum- insights and clinically relevant information on adverse marizing data and discussing illustrative patient cases event management in oncological practice that may concerning the management of adverse events across help to improve patient outcomes. oncological indications and affected organ systems. Conflict of interest M. Preusser has received honoraria for Drs. Scheiner and Pinter present a case of immune- lectures, consultationoradvisoryboardparticipationfromthe related hepatitis and dermatitis in a patient with following for-profit companies: Bayer, Bristol-Myers Squibb, hepatocellular carcinoma treated with nivolumab [1]. Novartis, Gerson Lehrman Group (GLG), CMC Contrast, Glax- Based on this case report, they discuss the incidence oSmithKline, Mundipharma, Roche, BMJ Journals, MedMe- dia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, and time of onset of immune checkpoint inhibitor Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee (ICI)-associated autoimmune hepatitis, the choice of Pharmaceuticals. immune-modulating medication, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Toxicity management in severe and refractory cases—what we have learned

Download PDF
1 page

Toxicity management in severe and refractory cases—what we have learned

Abstract

editorial memo (2022) 15:4 https://doi.org/10.1007/s12254-021-00788-0 Toxicity management in severe and refractory cases—what we have learned Matthias Preusser Accepted: 2 December 2021 © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2021 In this issue of the Magazine of European Medical On- Overall, the current collection of articles provides cology (MEMO), we provide a series of articles sum- insights and clinically relevant...
Loading next page...
 
/lp/springer-journals/toxicity-management-in-severe-and-refractory-cases-what-we-have-bQCzxtN17n
Publisher
Springer Journals
Copyright
2021 The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-021-00788-0
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2022) 15:4 https://doi.org/10.1007/s12254-021-00788-0 Toxicity management in severe and refractory cases—what we have learned Matthias Preusser Accepted: 2 December 2021 © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2021 In this issue of the Magazine of European Medical On- Overall, the current collection of articles provides cology (MEMO), we provide a series of articles sum- insights and clinically relevant information on adverse marizing data and discussing illustrative patient cases event management in oncological practice that may concerning the management of adverse events across help to improve patient outcomes. oncological indications and affected organ systems. Conflict of interest M. Preusser has received honoraria for Drs. Scheiner and Pinter present a case of immune- lectures, consultationoradvisoryboardparticipationfromthe related hepatitis and dermatitis in a patient with following for-profit companies: Bayer, Bristol-Myers Squibb, hepatocellular carcinoma treated with nivolumab [1]. Novartis, Gerson Lehrman Group (GLG), CMC Contrast, Glax- Based on this case report, they discuss the incidence oSmithKline, Mundipharma, Roche, BMJ Journals, MedMe- dia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, and time of onset of immune checkpoint inhibitor Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee (ICI)-associated autoimmune hepatitis, the choice of Pharmaceuticals. immune-modulating medication,

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Feb 1, 2022

Keywords: oncology; medicine/public health, general

References

  • Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
    M Pinter, B Scheiner
  • Checkpoint inhibitor pneumonitis: short review on literature and case report
    R Wass, D Lang, A Horner, B Lamprecht
  • Cardiotoxicity—current recommendations of prevention and treatment
    J Bergler-Klein
  • Clinical challenges in the management of endocrine side effects of immune-oncological therapies
    P Wolf, T Scherer